ADHD

Attention-deficit/hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric disorders in recent years, with an estimated global prevalence of 2.5% in adults and 5% in children. The condition causes trouble with maintaining attention,...

In the latest development of the criminal trial against FTX co-founder Sam Bankman-Fried, his legal team has sought court permission for their client to use ADHD medication during the trial to better focus. What Happened: As reported by Cointelegraph on Sunday, Bankman-Fried’s attorneys have...

The shortage of stimulant-based ADHD (Attention Deficit Hyperactivity Disorder) medications like Adderall, Vyvanse and Ritalin persists, with leading drug makers unable to provide a solution. The shortage began in Fall 2022 and was exacerbated by record-high prescription rates. Teva...

A biotech focused SPAC launched by frequent SPAC sponsor Chamath Palihapitiya announced a merger deal Wednesday morning. The SPAC Deal: Palihapitiya’s Social Capital Suvretta Holdings Corp I (NASDAQ: DNAA) announced a SPAC merger with Akili Interactive, valuing the company at an equity value...

Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention deficit hyperactivity disorder (ADHD) program in addition to a follow-up candidate soon to enter human trials and a...

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive topline results in late-stage trials. What Happened Supernus claimed that the daily active...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Ehave, Inc. (OTCMKTS:EHVVF) is a provider of digital therapeutics, delivering evidence-based therapeutic interventions to patients. ...

KemPharm Inc (NASDAQ: KMPH) shares plunged nearly 7 percent off Monday’s open despite news that its KP415 candidate for ADHD met primary and secondary endpoints in a pivotal efficacy and safety trial. What Happened The drug demonstrated statistically significant improvement on the SKAMP scale...

It’s every parent’s dream for their child to beg for a toy that costs as little as $5 and improves their focus, lowers their anxiety and relieves their stress. Anyone who has browsed Amazon.com, Inc. (NASDAQ: AMZN), eBay Inc (NASDAQ: EBAY) or Etsy Inc (NASDAQ: ETSY) looking for a fidget...

Cantor Fitzgerald's Maria Goldstein initiated Alcobra Ltd(NASDAQ: ADHD) at Buy with a price target of $16.00. Goldstein believes Alcobra's MDX, a non-stimulant-based drug to treat ADHD, has "an opportunity to achieve a statistically significant result with substantive hanged incorporated in the...